Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial-Reference-Cited by-同舟云学术

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

Published:2012-02 Issue:2 Volume:13 Page:135-144
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Untch Michael,Loibl Sibylle,Bischoff Joachim,Eidtmann Holger,Kaufmann Manfred,Blohmer Jens-Uwe,Hilfrich Jörn,Strumberg Dirk,Fasching Peter A,Kreienberg Rolf,Tesch Hans,Hanusch Claus,Gerber Bernd,Rezai Mahdi,Jackisch Christian,Huober Jens,Kühn Thorsten,Nekljudova Valentina,von Minckwitz Gunter

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006;Kaufmann;Ann Oncol,2007

2. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

3. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG Study Groups;Untch;J Clin Oncol,2011

4. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study;Untch;J Clin Oncol,2010

5. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial;Cameron;Oncologist,2010

Cited by 406 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis;Cancer Medicine;2024-07

2. On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer;2024-06-26

3. Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review;Breast Cancer Research;2024-05-22

4. Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance;Signal Transduction and Targeted Therapy;2024-04-03

5. Reporting on invasive lobular breast cancer in clinical trials: a systematic review;npj Breast Cancer;2024-03-20